Investigating the optimal soy protein and isoflavone intakes for women: A perspective

Women's Health

Volumn 4, Issue 4, 2008, Pages 337-356

  Messina, Mark ^a,b  

^a LOMA LINDA UNIVERSITY   (United States)

^b Nutrition Matters Inc   (United States)

Author keywords

China; Coronary heart disease; Hot flashes; Isoflavones; Japan; Osteoporosis; Protein; Recommended intake; Soyfoods

Indexed keywords

AGLYCONE; BIOCHANIN A; DAIDZEIN; FORMONONETIN; GENISTEIN; GLYCITEIN; ISOFLAVONE; PLACEBO; RALOXIFENE; SOYBEAN PROTEIN; TAMOXIFEN;

ARTERY COMPLIANCE; ARTERY ENDOTHELIUM; ARTICLE; ASIA; ATHEROSCLEROSIS; BONE DENSITY; BREAST CANCER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONGESTIVE CARDIOMYOPATHY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENDOCRINE DISEASE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FOOD ANALYSIS; FOOD COMPOSITION; FOOD INTAKE; FRAGILITY FRACTURE; GEOGRAPHIC DISTRIBUTION; HEART INFARCTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; NUTRIENT SUPPLY; NUTRITIONAL ASSESSMENT; NUTRITIONAL HEALTH; NUTRITIONAL VALUE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN INTAKE; QUALITY CONTROL; RISK REDUCTION; THYROID DISEASE; WOMEN'S HEALTH;

DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH PROMOTION; HOT FLASHES; HUMANS; ISOFLAVONES; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OSTEOPOROSIS, POSTMENOPAUSAL; PHYTOESTROGENS; SOYBEAN PROTEINS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WOMEN'S HEALTH;

EID: 48749112991     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.4.337     Document Type: Article

References (215)

1. Brzezinski A, Adlercreutz H, Shaoul R et al.: Short-term effect of phytoestrogen-rich diet on postmenopausal women. Menopause 489-494 (1997).
2. Diel P, Geis RB, Caldarelli A et al.: The differential ability of the phytoestrogen genistein and of estradiol to induce uterine weight and proliferation in the rat is associated with,a substance specific modulation of uterine gene expression. Mol. Cell. Endocrinol. 221(1-2), 21-32 (2004).
3. Yildiz MF, Kumru S, Godekmerdan A, Kutlu S: Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. Int. J Gynaecol. Obstet. 90(2), 128-133 (2005).
4. Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW: Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause 13(5), 831-839 (2006).
5. Ma DF, Qin LQ, Wang PY, Katoh R: Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. Eur. J Clin. Nutr. 62(2): 155-161 (2008).
6. Food Labeling Health Claims; Soy Protein and Coronary Heart Disease. Federal Register. (Volume 64, Number 206), 57699-57733 (1999).
7. Franke AA, Custer LJ, Wang W, Shi CY: HPLC analysis of isoflavonoids and other phenolic agents from foods and from human fluids. Proc. Soc. Exp. Biol. Med. 217(3), 263(1998).
8. Murphy PA, Barua K, Hauck CC: Solvent extraction selection in the determination of isoflavones in soy foods. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci 777 (1-2), 129-138 (2002).
9. Wiseman H, Casey K, Clarke DB, Barnes KA, Bowey E: Isoflavone aglycon and glucoconjugate content of high- and low-soy U.K. foods used in nutritional studies. J. Agric. Food Chem. 50(6), 1404-1410 (2002).
10. Bovee TF, Helsdingen RJ, Rietjens IM, Keijer J, Hoogenboom RL: Rapid,yeast estrogen bioa ssays stably expressing human estrogen receptors α and β and green fluorescent protein: a comparison of different compounds with both receptor types. J. Steroid Bjocbem. Mol. Biol. 91(3), 99-109 (2004).
11. Walsh KR, Haak SJ, Bohn T, Tian Q, Schwartz SJ, Failla ML. Isoflavonoid glucosides are deconjugated and absorbed in the small intestine of human subjects with ileostomies. Am. J. Clin. Nutr. 85(4), 1050-1056 (2007).
12. Setchell KD, Brown NM, Zimmer-Nechemias L et al.: Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am. J. Clin. Nutr. 76(2), 447-453 (2002).
13. Tsai HS, Huang LJ, Lai YH, Chang JC, Lee RS, Chiou RY: Solvent effects on extraction and HPLC analysis of soybean isonavones and variations of isonavone compositions as affected by crop season. J. Agric. Food Chem. 55(19), 7712-7715 (2007).
14. Nielsen IL, Williamson G. Review of the factors affecting bioavailability of soy isoflavones in humans. Nutr Cancer 57(1), 1-10 (2007).
15. Maskarinec G, Watts K, Kagihara J, Hebshi SM, Franke AA: Urinary isoflavonaid excretion is similar after consuming soya milk and miso soup in Japanese-American women. Br. J. Nutr. 1-6 (2008).
16. Zheng Y, Lee SO, Verbruggen MA, Murphy PA, Hendrich S: The apparent absorptions is of isoflavone glocosides and aglucons are similar in women and are increased by rapid gut transit time and low fecal isoflavone degradation. J. Nutr. 134(10), 2534-2539 (2004).
17. Erdman JW Jr, Badger TM, Lampe JW, Setchell KD, Messina M: Not all soy products are created equal: caution needed in interpretation of research results. J. Nutr. 134(5), 1229S-1233S (2004).
18. Lee SJ, Ahn JK, Khanh TD et al.: Comparison of isoflavone concentrations in soybean (Glycine max (L.) Merrill) sprouts grown under two different light conditions. J. Agric. Food Chem. 55(23), 9415-9421 (2007).
19. Tsukamoto C, Shimada S, Igita K et al.: Factors affecting isoflavone content in soybean seeds: changes in isoflavones, saponins, and composition of fatty acids at different temperatures during seed development. J. Agric. Food Chem. 431184-431192 (1995).
20. Messina M, Nagata C, Wu AH: Estimated Asian adult soy protein and isoflavone intakes. Nutr. Cancer 55(1), 1-12 (2006).
21. 3H]oestradiol by uterus, vagina and skeletal muscle of immature mice. J. Endocrinol. 44(2), 213-218 (1969).
22. Dip R, Lenz S, Antignac JP, Le Bizec B, Gmuender H, Naegeli H: Global gene expression profiles induced by phytoestrogens in human breast cancer cells. Endocr Relat. Cancer 15(1), 161-173 (2008).
23. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 93(12), 5925-5930 (1996).
24. Kuiper GG, Lemmen JG, Carlsson B et al.: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139(10), 4252-4263 (1998).
25. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A: Bioavadability of phyto-oestrogens. Br. J. Nutr. 89(Suppl. 1), S45-S58 (2003).
26. Jordan VC, Brodie AM: Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72(1), 7-25 (2007).
27. Hunter T, Cooper JA: Protein-tyrosine kinases. Annu. Rev. Biochem. 54, 897-930 (1985).
28. Sarkar FH, Li Y: Soy isoflavones and cancer prevention. Cancer Invest. 21(5), 744-757 (2003).
29. Banerjee S, Li Y, Wang Z, Sarkar FH: Multi-targeted therapy of cancer by genistein. Cancer Lett. DOI: 10.1016/j.canlet.2008.03.052 (2008) (Epub ahead of print).
30. Simoons FJ: Food in China. A Cultural and Historical Inquiry. CRC Press, Boca Raton, FL, USA (1991).
31. Liu Z, Li W, Sun J et al.: Intake of soy foods and soy isoflavones by rural adult women in China. Asia Pac. J. Clin. Nutr. 13(2), 204-209 (2004).
32. Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K: Soy product intake is inversely associated with serum homocysteine level in premenopausal Japanese women. J. Nutr. 133(3), 797-800 (2003).
33. Nagata C, Takatsuka N, Kawakami N, Shimizu H: Association of that with the onset of menopause in Japanose women. Am. J. Epidemiol. 152(9), 8631-867 (2000).
34. Nagata C, Takatsuka N, Kawakami N, Shimizu H: A prospective cohort study of soy product intake and stomach cancer death. Br. J. Cancer 87(1), 31-36 (2002).
35. Takata Y, Maskarinec G, Franke A, Nagata C, Shimizu H: A comparison of dietary habits among women in Japan and Hawaii. Public Health Nutr. 7(2), 319-326 (2004).
36. Nagata C, Takatsuka N, Kurisu Y, Shimizu H: Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women. J Nutr. 128(2), 209-213 (1998).
37. Tanaka K, Sasaki S, Murakami K, Okubo H, Takahashi Y, Miyake Y: Relationship between soy and isoflavone intake and periodontal disease: the Freshmen in Dietetic Courses Study II. BMC Public Health 8(1), 39 (2008).
38. Miyake Y, Sasaki S, Ohya Y et al.: Soy. isoflavones, and prevalence of allergic rhinitis in Japanese women: the Osaka Maternal and Child Health Study. J Allergy Clin. Immunol. 115(6) 1176-1183 (2005).
39. Zhang X, Shu XO, Gao YT et al.: Soy food consumption is associated with lower risk of coronary heart disease in Chinese. women. J. Nutr. 133(9), 2874-2878 (2003).
40. Lee SA, Wen W, Xiang YB et al.: Assessment of dietary lsoflavone intake among middle-aged chinese men. J. Nutr. 137(4), 1011-1016 (2007).
41. Yang G, Shu XO, Jin F et al.: Longitudinal study of soy food intake and blood pressure among middle-aged and elderly Chinese women. Am. J. Clin. Nutr. 81(5), 1012-1017 (2005).
42. Dai Q, Shu XO, Jin F et al.: Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br. J. Cancer 85(3), 372-378 (2001).
43. Nagata C, Hirokawa K, Shimizu N, Shimizu H: Soy, fat and, other dietary factors in relation to premenstrual symptoms in Japanese women. BJOG 111(6), 594-599 (2004).
44. Nagata C, Takatsuka N, Kawakami N, Shimizu H: Soy product intake and premenopausal hysterectomy in a follow-up study of Japanese women. Eur. J. Clin. Nutr. 55(9), 773-777 (2001).
45. Arai Y. Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinae N: Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J. Nutr. 130(9), 2243-2250 (2000).
46. Somekawa Y, Chiguchi M, Ishibashi T, Aso T: Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet. Gynecol. 97(1), 109-115 (2001).
47. Ishihara J, Sobue T, Yamamoto S, Sasaki S, Tsugane S: Demographics, lifestyles, health characteristics, and dietary intake among dietary supplement users in Japan. Int. J. Epidemiol. 32(4), 546-553 (2003).
48. Wakai K, Egami I, Kato K et al.: Dietary intake and sources of isoflavones among Japanese. Nutr. Cancer 33(2), 139-145 (1999).
49. Nagata C: Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Int. J. Epidemiol. 29(5), 832-836 (2000)
50. Kikuchi Y, Shimamura Y, Hirokado M, Yasuda K, Nishijma M: Daily intake of isoflavones based on the market basket method. Shokuhin Eiseigaku Zasshi 42(2), 122-127 (2001).
51. Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S: Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol. Biomarkers Prev. 16(3), 538-545 (2007).
52. Nagata Y, Sonoda T, Mori M et al.: Dietary isoflavones may protect against prostate cancer in Japanese men. J. Nutr. 137(8), 1974-1979 (2007).
53. Yamamoto S, Sobue T, Sasaki S et al.: Validity and reproducibility of a self-administered food-frequency questionnaire to assess isoflavone intake in a Japanese population in comparison with dietary records and blood and urine isoflavones. J. Nutr. 131(10), 2741-2747 (2001).
54. Arai Y, Uehara M, Sato Y et al.: Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J. Epidemiol. 10(2), 127-135 (2000).
55. Takashima N, Miyanaga N, Komiya K, More M, Akaza H: Blood isoflavone levels during intake of a controlled hospital diet. J. Nutr. Sci. Vitaminol. (Tokyo) 50(4) 246-252 (2004).
56. Balk E, Chung M, Chew P et al.: Effects of soy on health outcomes. Evidence report/technology assessment no. 126 (prepared by Tufts-New England Medical Center Evidence-based Practice Center under contract no. 290-02-0022) AHRQ Publication no. 05-EO24-2, Rockville, MD Agency for Healthcare Research and Quality (2005).
57. Cassidy A, Albertazzi P, Lise Nielsen I et al.: Critical review of health effects of soyabean phyto-oestrogeris in post-menopausal women. Proc. Nutr. Soc. 65(1), 76-92 (2006).
58. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr: Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr. 68(6 Suppl.), 1375S-1379S (1998).
59. Messina M, Ho S, Alekel DL: Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin. Clin. Nutr. Metab. Care 7(6), 649-658 (2004).
60. Ma DF, Qin LQ, Wang PY, Katoh R: Soy isoflavone intake increases bone mineral density in the spine of menopausal women: Meta-analysis of randomized controlled trials. Clin. Nutr. 27(1), 57-64. (2007).
61. Marina H, Minutoli L, Polito F et al.: Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann. Intern. Med. 146(12), 839-847 (2007).
62. Brink E, Coxam V, Robins S, Wahala K, Cassidy A, Branca F: Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study. Am. J. Clin. Nutr. 87(3), 761-770 (2008).
63. Murkies AL, Lombard C, Strauss BJ, Wilcox C, Burger HC, Morton MS: Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas 21(3), 189-195 (1995).
64. Howes LG, Howes JB, Knight DC: Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas 55(3), 203-211 (2006).
65. Messina M, Hughes C: Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J. Med. Food 6(1), 1-11 (2003).
66. Lethaby A, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J: Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst. Rev. (4), CDO01395 (2007).
67. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ: Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet. Gynecol. 104(4), 824-836 (2004).
68. Nelson HD: Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291(13), 1610-1620 (2004).
69. de Lima Toccafondo Vieira M, Duarte RF, Campos LM, Nunan Ede A: Comparison of the estrogenic potencies of standardized soy extracts by immature rat uterotrophic bioassay. Phytomedicine 15(1-2), 31-37 (2008).
70. Nahas EA, Nahas-Netu J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R: Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 58(3), 249-258 (2007).
71. D'Anna R, Cannata ML, Atteritano M et al.: Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. Menopause 14(4), 648-655 (2007).
72. Cheng G, Wilczek B, Warner M, Gustafsson JA, Landgeen BM: Isoflavone treatment for acute menopausal symptoms. Menopause 14(3 Pt 1), 468-473 (2007).
73. Cheng G, Warner M, Gustafsson JA, Landgren BM: Letter to the editor. Menopause 14(5), 958-959 (2007).
74. Nestel PJ, Yamashita T, Sasahara T et al.: Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler. Thromb. Vasc. Biol. 17(12), 3392-3398 (1997).
75. Teede HI, McGrath BP, DeSilva L, Cehun M, Fassoulakis A, Nestel PJ: Isoflavones reduce arterial stiffness: a placebo-controlled study in men and postmenopausal women. Arterioscler. Thrumb. Vasc. Biol. 23(6), 1066-1071 (2003).
76. Herrington DM, Brown WV, Mosca L et al.: Relationship between arterial stiffness and subclinical aortic atherosclerosis. Circulation 110(4), 432-437 (2004).
77. Hedlund J, Bugel S, Tholstrup T et al.: Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. Br. J. Nutr. 95(6), 1120-1126 (2006).
78. Meyer BJ, Larkin TA, Owen AJ, Astheimer LB, Tapsell LC, Howe PR: Limited lipid-lowering effects of regular consumption of whole soybean foods. Ann. Nutr. Metab. 48(2), 67-78 (2004).
79. Teede HJ, Giannopoulos D, Dalais FS, Hodgson J, McGrath BP: Randomised, controlled, cross-over trial of soy protein with isoflavones on blood pressure and arterial function in hypertensive subjects. J. Am. Coll. Nutr. 25(6), 533-540 (2006).
80. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 23(2), 168-175 (2003).
81. Walker HA, Dean TS, Sanders TA, Jackson G, Ritter JM, Chowienczyk PJ: The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17b-estradiol. Circulation 103(2), 258-262 (2001).
82. Squadrito F, Altavilla D, Crisafulli A et al.: Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am. J. Med. 114(6), 470-476 (2003).
83. Squadrito F, Altavilla D, Morabito N et al.: The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis 163(2), 339-347 (2002).
84. Colacurci N, Chiantera A, Fornaro F et al.: Effects of soy isoflavones on endothelial function in healthy postmenopausal women. Menopause 12(3), 299-307 (2005).
85. Cupisti A, Ghiadoni L, D'Alessandro C et al.: Soy protein diet improves endothelial dysfunction in renal transplant patients. Nepbrol. Dial. Transplant. 22(1), 229-234 (2007).
86. Katz DL, Evans MA, Njike VY et al.: Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women. Climacteric 10(6), 500-507 (2007).
87. Matthan NR, Jalbert SM, Ausman LM, Kuvin JT, Karas RH, Lichtenstein AH: Effect of soy protein from differently processed products on cardiovascular disease risk factors and vascular endothelial function in hypercholesterolemic subjects. Am. J. Clin. Nutr. 85(4), 960-966 (2007).
88. Messina M: Western soy intake is too low to produce health effects. Am. J. Clin. Nutr. 80(2), 528-529 (2004).
89. Lamartiniere CA, Zhao YX, Fritz WA: Genistein: mammary cancer chemoprevention, in vivo mechanisms of action, potential for toxicity and bioavailability in rats. J. Womem Cancer 211-219 (2000).
90. Korde L, Fears T, Wu A et al.: Adolescent and childhood soy intake and breast cancer risk in Asian-American women. Breast Cancer Res. Treat. 88(Suppl. 1), S149 (2005).
91. Shu XO, Jin F, Dai Q et al.: Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol. Biomarkers Prev. 10(5), 483-488 (2001).
92. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC: Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 23(9), 1491-1496 (2002).
93. Weghuber D, Widhalm K: Effect of 3-month treatment of children and adolescents with familial and polygenic hypercholesterolaemia with a soya-substituted diet. Br. J. Nutr. 99(2), 281-286 (2008).
94. Widhalm K, Brazda G, Schneider B, Kohl S: Effect of soy protein diet versus standard low fat, low cholesterol diet on lipid and lipoprotein levels in children with familial or polygenic hypercholesterolemia. J. Pediatr. 123(1), 30-34 (1993).
95. Sasazuki S: Case control study of nonfatal myocardial infarction in relation to selected foods in Japanese men and women. Jpn. Circ. J. 65(3), 200-206 (2001).
96. Kokubo Y, Iso H, Ishibara J, Okada K, Inoue M, Tsugane S: Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Healtlh Center-based (JPHC) study cohort I. Circulation 116(22), 2553-2562 (2007).
97. Ross PD, He Y, Yates AJ et al.: Body size accounts for most differences in bone density between Asian and Caucasian women. The EPIC (Early Postmenopausal Interventional Cohort) study gGroup. Calcif. Tissue Int. 59(5), 339-343 (1996).
98. Russell-Aulet M, Wang J, Thornton JC, Colt EW, Pierson RN Jr: Bone mineral density and mass in a cross-sectional study of white and Asian women. J. Bone Miner. Res. 8(5), 575-582 (1993).
99. Nomura A, Wasnich RD, Heilbrun LK, Ross PD, Davis JW: Comparison of bone mineral content between Japan-born and US-born Japanese subjects in Hawaii. Bone Miner. 6(2), 213-223 (1989).
100. Ross PD, Fujiwara. S, Huang C et al.: Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int. J. Epidemiol. 24(6), 1171-1177 (1995).
101. Lau EM, Chan HH, Woo J et al.: Normal ranges for vertebral height ratios and prevalence of vertebral fracture in Hong Kong Chinese: a comparison with American Caucasians. J. Bone Miner. Res. 11(9), 1364-1368 (1996).
102. Dennison E, Yoshimura N, Hashimoto T, Cooper C: Bone loss in Great Britain and Japan: a comparative longitudinal study. Bone 23(4), 379-382 (1998).
103. Tsai K, Huang K, Chieng P, Su C: Bone mineral density of normal Chinese women in Taiwan. Calcif. Tissue Int. 48, 161-166 (1991).
104. Tsai K, Twu S, Chieng P, Yang R, Lee T. Prevalence of vertebral fractures in chinese men and women in urban Taiwanese communities. Calcif. Tissue Int. 59(4), 249-253 (1996).
105. Ho SC, Chan SC, Yip YB, Chan CS, Woo JL, Sham A: Change in bone mineral density and its determinants in pre- and perimenopausal Chinese women: the Hong Kong perimenopausal women osteoporosis study. Osteoporos. Int. (2008) (Epub ahead of print).
106. Zhang X, Shu XO, Li H et al.: Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arcb. Intern. Med. 165(16), 1890-1895 (2005).
107. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M: Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113(7), 1034-1044 (2006).
108. Tonstad S, Smerud K, Hoie L: A comparison of the effects of 2 doses of soy protein or casein on serum lipids, serum lipoproteins, and plasma total homocysteine in hypercholesterolemic subjects. Am. J. Clin. Nutr. 76(1), 78-84 (2002).
109. Teixeira SR, Potter SM, Weigel R, Hannum S, Erdman JW Jr, Hasler CM: Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Am. J. Clin. Nutr. 71(5), 1077-1084 (2000).
110. Takatsuka N, Nagata C, Kurisu Y, Inaba S, Kawakami N, Shimizu H: Hypocholesterolemic effect of soymilk supplementation with usual diet in premenopausal normolipidemic japanese women. Prev. Med. 31(4), 308-314 (2000).
111. Genovese MI, Barbosa AC, Pinto Mda S, Lajolo FM: Commercial soy protein ingredients as isoflavone sources for functional foods. Plant Foods Hum. Nutr. 62(2), 53-58 (2007).
112. Smit E, Nieto FJ, Crespo CJ, Mitchell P: Estimates of animal and plant protein intake in US adults: results from the Third National Health and Nutrition Examination Survey, 1988-1991. J Am. Diet. Assoc. 99(7), 813-820 (1999).
113. Schultz J: Food fight: NCI aims for consumer clarity with complaint against dairy group. J. Natl Cancer Inst. 95(13), 934-935 (2003).
114. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. AICR, Washington, DC, USA (2007).
115. Drescher LS, Fhiele S, Mensink GB: A new index to measure healthy food diversity better reflects a healthy diet than traditional measures. J. Nutr. 137(3), 647-651 (2007).
116. A Report of the Panel on Macronutrients, Subcommittees on upper reference levels of nutrients and interpretation and uses of dietary reference intakes, and the Standing Committee on the scientific evaluation of dietary reference intakes: Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). The National Academies Press, Washinton, DC (2002).
117. Humayun MA, Elango R, Ball RO, Pencharz PB: Reevaluation of the protein requirement in young men with the indicator amino acid oxidation technique. Am. J. Clin. Nutr. 86(4), 995-1002 (2007).
118. Astrup A: The satiating power of protein - a key to obesity prevention? Am. J. Clin. Nutr. 82(1), 1-2 (2005).
119. Bonjour JP: Dietary protein: air essential nutrient for bone health. J. Am. Coll. Nutr. 24(6 Suppl.), 526S-536S (2005).
120. Houston DK, Nicklas BJ, Ding J et al.: Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) study. Am. J. Clin. Nutr. 87(1), 150-155 (2008).
121. Martin DS: Dietary protein and hypertension: where do we stand? Nutrition 19(4), 395-386 (2003).
122. Campbell B, Kreider RB, Ziegenfuss T et al.: International Society of Sports Nutrition Position Stand: protein and exercise. J. Int. Soc. Sports Nutr. 4(1), 8 (2007).
123. Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D, Curhan GC: The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann. Intern. Med. 138(6), 460-467 (2003).
124. Crittenden RG, Bennett LE: Cow's milk allergy: a complex disorder. J. Am. Coll. Nutr. 24(6. Suppl.), 582S-591S (2005).
125. Kokkonen J, Haapalahti M, Tikkanen S, Karttunen R, Savilahti E: Gastrointestinal complaints and diagnosis in children: a population-based study. Acta Paediatr. 93(7), 880-886 (2004).
126. van der Pols JC, Bain C, Gunnell D, Smith GD, Frobisher C, Martin RM: Childhood dairy intake and adult cancer risk: 65-y follow-up of the Boyd Orr cohort. Am. J. Clin. Nutr. 86(6), 1722-1729 (2007).
127. Ahn J, Albanes D, Peters U et al.: Dairy products, calcium intake, and risk of prosiate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol. Biomarkers Prev. 16(12), 2623-2630 (2007).
128. Goldfarb MF: Relation of time of introduction of cow milk protein to an infant and risk of Type-1 diabetes mellitus. J. Proteoine Res. 7(5). 2165-2167 (2008).
129. Frias J, Song YS, Martinez-Vilialuenga C, Gonzalez de Mejia E, Vidal-Valverde C: Immunoreactivity and amino acid content of fermented soybean products. J. Agric. Food Chem. 56(1), 99-105 (2008).
130. Vierk KA, Koehler KM, Fein SB, Street DA: Prevalence of self-reported food allergy in American adults and use of food labels. J. Allergy Clin. Immunol. 119(6), 1504-1510 (2007).
131. Hurrell RF: Influence of vegetable protein sources on trace element and mineral bioavailability. J. Nutr. 133(9), 2973S-2977S (2003).
132. Bhartia J, Greer F: Use of soy protein-based formulas in infant feeding. Pediatrics 121(5), 1062-1068 (2008).
133. Caserta D, Maranghi L, Mantovani A, Marci R, Maranghi F, Moscarini M: Impact of endocrine disruptor chemicals in gynamology. Hum. Reprod. Update 14(1), 59-72 (2008).
134. Vilela ML, Willingham E, Buckley J et al.: Endocrine disruptors and hypospadias: role of genistein and the fungicide vinclozolin. Urology 70(3), 618-621 (2007).
135. White LR, Petrovitch H, Ross GW et al.: Brain aging and midlife tofu consumption. J. Am. Coll. Nutr. 19(2), 242-255 (2000).
136. LeBlanc ES, Janowsky J, Chan BK, Nelson HD: Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285(11), 1489-1499 (2001).
137. Woo J, Lynn H, Lau WY et al.: Nutrient intake and psychological health in an elderly Chinese population. Int. J. Geriatr. Psychiatry 21(11), 1036-1043 (2006).
138. Zhao L, Brinton RD: WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Rev. Neurother. 7(11), 1549-1564 (2007).
139. Mazer NA: Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women. Thyroid 14(Suppl. 1), S27-S34 (2004).
140. Divi RL, Doerge DR: Inhibition of thyroid peroxidase by dietary flavonoids. Chem. Res. Toxicol. 9(1), 16-23 (1996).
141. Divi RL, Chang HC, Doerge DR: Anti-thyroid isoflavones from soybean: isolation, characterization, and mechanisms of action. Biochem. Pharmacol. 54(10), 1087-1096 (1997).
142. Chang HC, Doerge DR: Dietary genistein inactivates rat thyroid peroxiclase in vivo without an apparent hypothyroid effect. Toxicol Appl. Pharmacol. 168(3), 244-252 (2000).
143. Poirler LA, Doerge DR, Gaylor DW et al.: An FDA review of sulfamethazine toxicity. Regul. Toxicol Pharmacol. 30(3), 217-222 (1999).
144. Messina M, Redmond G: Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16(3), 249-258 (2006).
145. Khaodhiar L, Ricciotti HA, Li L et al.: Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 15(1), 125-132 (2008).
146. Romualdi D, Costantini B, Campagna G, Lanzone A, Guido M: Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study. Fertil. Steril. (2007) (Epub ahead of print).
147. Teas J, Braverman LE, Kurzer MS, Pion S, Hurley TG, Hebert JR: Seaweed and soy: companion foods in Asian cuisine and their effects on thyroid function in American women. J. Med. Food 10(1), 90-100 (2007).
148. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR: Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid 17(12), 1211-1223 (2007).
149. Doerge DR, Sheehan DM: Goitrogenic and estrogenic activity of soy isoflavones. Environ. Health Perspect. 110(Suppl.) 3349-3353 (2002).
150. Fitzpatrick M: Soy formulas and the effects of isoflavones on the thyroid. N. Z. Med. J. 113(1103), 24-26 (2000).
151. Bell DS, Ovalle F: Use of soy protein supplement and resultant need for increased dose of levothyroxine. Endocr. Pract. 7(3), 193-194 (2001).
152. Conrad SC, Chiu H, Silverman BL: Soy formula complicates management of congenital hypothyroidism. Arch. Dis. Child. 89(1), 37-40 (2004).
153. Liel Y, Harman-Boehm I, Shany S: Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J. Clin. Endocrinol. Metab. 81(2), 857-859 (1996).
154. Chiu AC, Sherman SI: Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid 8(8), 667-671 (1998).
155. Shakir KM, Chute JP, Aprill BS, Lazarus AA: Ferrous sulfate-induced increase in requirement for thyroxine in a patient with primary hypothyroidism. South Med. J. 90(6), 637-639 (1997).
156. Liel Y, Sperber AD, Shany S: Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am. J. Med. 97(4), 363-365 (1994).
157. Sperber AD, Liel Y: Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch. Intern. Med. 152(1), 183-184 (1992).
158. Sherman SI, Tielens ET, Ladenson PW: Sucralfate causes malabsorption of L-thyroxine. Am. J. Med. 96(6), 531-535 (1994).
159. Siraj ES, Gupta MK, Reddy SS: Raloxifene causing malabsorption of levothyroxine. Arch. Intern. Med. 163(11), 1367-1370 (2003).
160. Rosenberg R: Malabsorption of thyroid hormone with cholestyramine administration. Conn. Med. 58(2), 109 (1994).
161. Harmon SM, Seifert CF: Levothyroxine-cholestyramine interaction reemphasized. Ann. Intern. Med. 115(8), 658-659 (1991).
162. Cassidy A, Bingham S, Setchell KD: Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am. J. Clin. Nutr. 60(3), 333-340 (1994).
163. Nagata C, Kabuto M, Kurisu Y, Shimizu H: Decreased serum estradiol concentration associated with high dietary intake of soy products in premenopausal Japanese women. Nutr. Cancer 29(3), 228-233 (1997).
164. Brown BD, Thomas W, Hutchins A, Martini MC, Slavin JL: Types of dietary fat and soy minimally affect hormones and biomarkers associated with breast cancer risk in premenopausal women. Nutr Cancer 43(1), 22-30 (2002).
165. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS: Modest hormonal effects of soy isoflavones in postmenopausal women. J. Clin. Endocrinol. Metab. 84(10), 3479-3484 (1999).
166. Rice S, Mason HD, Whitehead SA: Phytoestrogens and their low dose combinations inhibit mRNA expression and activity of aromatase in human granulosaluteal cells. J. Steroid Biochem. Mol. Biol. 101(4-5), 216-225 (2006).
167. Lacey M, Bohday J, Fonseka SM, Ullah AI, Whitehead SA: Dose-response effects of phytoestrogens on the activity and expression of 3β-hydroxysteroid dehydrogenase and aromatase in human granulosa-luteal cells. J. Steroid Biochem. Mol. Biol. 96(3-4), 279-286 (2005).
168. Kaaks R, Lukanova A, Kurzer MS: Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 11(12), 1531-1543 (2002).
169. Weiderpass E, Adami HO, Baron JA et al.: Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Canser Inst. 91(13), 1131-1137 (1999).
170. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 10(2), 113-132 (2003).
171. Chandrareddy A, Muneyyirci-Delale O, McFarlane SI, Murad OM: Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement. Ther. Clin. Pract. 14(2), 132-135 (2008).
172. Johnson EB, Muto MG, Yanushpolsky EH, Mutter GL: Phytoestrogen supplementation and endometrial cancer. Obstet. Gynecol. 98(5 Pt 2), 947-590 (2001).
173. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC: Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil. Steril. 82(1), 145-148 (2004).
174. Foth D, Nawroth F: Effect of phytoestrogens on the endometrium? Fertil. Steril. 83(1), 256-257; author reply 257 (2005).
175. Hsieh CY, Santell RC, Haslam SZ, Helferich WG: Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 58(17), 3833-3838 (1998).
176. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG: Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J. Nutr. 131(11), 2957-2962 (2001).
177. Allred CD, Ju YH, Allred KF, Chang J. Helferich WG: Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis 22(10), 1667-1673 (2001).
178. Allred CD, Allred KF, Ju YH, Virant SM. Helferich WG: Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 61(13), 5045-5050 (2001).
179. Allred CD, Allred KF, Ju YH, Goeppinger TS, Doerge DR, Helferich WG: Soy processing influences growth of estrogen-dependent breast cancer tumors. Carcinogenesis 25(9), 1649-1657 (2004).
180. Anupongsanugool E, Teekachunhatean S, Rojanasthien N, Pongsatha S, Sangdee C: Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women. BMC Clin. Pharmacol. 5(2), 1-10 (2005).
181. Ryan-Borchers TA, Park JS, Chew BP, McGuire MK, Fournier LR, Beerman KA: Soy isoflavones modulate immune function in healthy postmenopausal women. Am. J. Clin. Nutr. 83(5), 1118-1125 (2006).
182. Sartippour MR, Rao JY, Apple S et al.: A pilot clinical study of short term isoflavone supplements in breast cancer patients. Nutr Cancer 49(1), 59-65 (2004).
183. Palomares MR, Hopper L, Goldstein L, Lehman CD, Storer BE, Gralow JR: Effect of soy isoflavones on breast proliferation in postmenopausal breast cancer survivors. Breast Cancer Res. Treat. 88(Suppl. 1), 4002 (2004).
184. Hargreaves DF, Pqtten CS, Harding C et al.: Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J. Clin. Endocrinol. Metab. 84(11), 4017-4024 (1999).
185. Maskarinec G, Williams AE, Carlin L: Mammographic densities in a one-year isoflavone intervention. Eur. J. Cancer Prev. 12(2), 165-169 (2003).
186. Maskarinec G, Franke AA, Williams AE et al.: Effects of a 2-year randomized soy intervention on sex hormone levels in premenopausal women. Cancer Epidemiol. Biomarkers Prev. 13(11), 1736-1744 (2004).
187. Atkinson C, Warren RM, Sala E et al.: Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial. Breast Cancer Res. 6(3), R170-R179 (2004).
188. Messina M, McCaskill-Stevens W. Lampe JW: Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J. Natl Cancer Inst. 98(18), 1275-1284 (2006).
189. Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R: Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause Int. 14(1), 6-12 (2008).
190. Boyapati SM, Shu XO, Ruan ZX et al.: Soyfood intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study. Breast Cancer Res. Treat. 92(1), 11-17 (2005).
191. Fink BN, Steck SE, Wolff MS et al.: Dietary flavonoid intake and breast cancer survival among women on Long Island. Cancer Epidemiol. Biomarkers Prev. 16(11), 2285-2292 (2007).
192. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84(12), 4559-4565 (1999).
193. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G: Postmenopausal hormone therapy and change in mammographic density. J. Natl Cancer Inst. 95(1), 30-37 (2003).
194. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
195. Doyle C, Kushi LH, Byers T et al.: Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J. Clin. 56(6), 323-353 (2006).
196. Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R: Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 58(3), 249-258 (2007).
197. Zhang B, Chen YM, Huang LL et al.: Greater habitual soyfood consumption is associated with decreased carotid intima-media thickness and better plasma lipids in Chinese middle-aged adults. Atherosclerosis 198(2), 403-411 (2008).
198. Ho SC, Woo JL, Leung SS, Sham AL, Lam TH, Janus ED: Intake of soy products is associated with better plasma lipid profiles in the Hong Kong Chinese population, J. Nutr. 130(10), 2590-2593 (2000).
199. Schryver T, Smith C, Wall M: Self-identities and BMI of Minnesotan soy consumers and non-consumers. Obesity (Silver Spring) 15(5), 1101-1106 (2007).
200. Tamura A, Shiomi T, Hachiya S, Shigematsu N, Hara H: Low activities of intestinal lactase suppress the early phase absorption of soy isoflavones in Japanese adults. Clin. Nutr. 27(2), 248-253 (2008).
201. Setchell KD, Brown NM, Lydeking Olsen E: The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J. Nutr. 132(12), 3577-84 (2002).
202. Gardner CD, Messina M, Kiazand A, Morris JL, Franke AA: Effect of two types of soy milk and dairy milk on plasma lipids in hypercholesterolemic adults: a randomized trial. J. Am. Coll. Nutr. 26(6), 669-677 (2007).
203. Ma DF, Qin LQ, Wang PY, Katoh R: Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized cotrolled trials. Clin. Nutr. 27(1), 57-64 (2008).
204. Albanes D, Heinonen OP, Taylor PR et al.: α-tocopherol and β-carotene supplements and lung cancer incidence in the α-tocopherol, β-carotene cancer prevention study: effects of base-line characteristics and study compliance. J. Natl Cancer Inst. 88(21), 1560-1570 (1996).
205. Lichtenstein AH: Nutrients and cardiovascular disease: no easy answers. Curr. Opin. L~pidoL 16(l), 1-3 (2005). 206.Pritchard KI: Should observational studies be a thing of the past? j had Cancer 1rut. 100(7), 451-452 (2008).
206. Lissin LW, Oka R, Lakshmi S, Cooke JP: Isoflavones improve vascular reactivity in post-menopausal women with hypercholesterolemia. Vasc. Med. 9(1), 26-30 (2004).
207. Rivas M, Garay RP, Escanero F, Cia P Jr, Cia F, Aida JO: Soy milk lowers blood pressure in men and women with mild to moderate essential hypertension. J. Nutr. 132(7), 1900-1902 (2002).
208. Welty FK, Lee KS, Lew NS, Zhou JR: Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive, and normotensive postmenopausal women. Arch. Intern. Med. 167(10). 1060-1067 (2007).
209. Kuba M, Tana Tawata S, Yasuda M: Production of angiotensin 1-converting enzyme inhibitory peptides from soybean protein with Monascus purpureus acid proteinase. Process Biochemi 40, 2191-2196 (2005).
210. Messina M, Kucuk O, Lampe JW: An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J. AOAC Int. 89(4), 1121-1134 (2006).
211. Setchell KD, Brown NM, Desai P et al.: Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr. 131(4), 1362S-1375S (2001).
212. Chua R, Anderson K, Chen J, Hu M: Quality, labeling accuracy, and cost comparison of purified soy isoflavonoid products. J. Altern. Complement. Med. 10(6), 1053-1060 (2004).
213. Xiao CW: Health effects of soy protein and isoflavones in humans. J. Nutr. 138(6), 1244S-1249S (2008).
214. Ishizuki Y, Hirooka Y, Murata Y, Togashi K: [The effects on the thyroid gland of soybeans administered experimentally to healthy subjects]. Nippon Naibunpi Gakkai Zasshi 67, 622-629 (1991).
215. Murphy PA, Song T, Buseman G et al.: Isoflavones in retail and institutional soy foods. J. Agric. Food Chem. 47(7), 2697-2704 (1999).